NYSEMKT: INFUInfusystem Holdings Inc Stock
$7.02+0.44 (+6.69%)
Updated Oct 3, 2024
INFU Price
$7.02
Fair Value Price
N/A
Market Cap
$149.63M
52 Week Low
$5.74
52 Week High
$10.99
P/E
702x
P/B
2.8x
P/S
1.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$129.37M
Earnings
$366.00k
Gross Margin
49.7%
Operating Margin
2.99%
Profit Margin
0.3%
Debt to Equity
1.03
Operating Cash Flow
$12M
Beta
0.91
Next Earnings
Nov 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INFU Overview
InfuSystem Holdings, Inc. engages in the provision of health care services. The company is headquartered in Madison Heights, Michigan and currently employs 238 full-time employees. The firm delivers local, field-based customer support and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. Its service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics for the treatment of a range of cancers, including colorectal cancer, pain management and other disease states. The company sells or rents new and pre-owned pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings, including home care and home infusion providers, skilled nursing facilities, pain centers and others.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INFU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INFU was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INFU is poor value based on its earnings relative to its share price (702x), compared to the US market average (26.22x)
P/E vs Market Valuation
INFU is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more INFU due diligence checks available for Premium users.
Be the first to know about important INFU news, forecast changes, insider trades & much more!
INFU News
Valuation
INFU price to earnings (PE)
For valuing profitable companies with steady earnings
Company
702x
Industry
-61.62x
Market
26.22x
INFU is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INFU is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
INFU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.8x
Industry
3.96x
INFU is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INFU's financial health
Profit margin
Revenue
$33.7M
Net Income
$717.0k
Profit Margin
2.1%
INFU's Earnings (EBIT) of $3.86M... subscribe to Premium to read more.
Interest Coverage Financials
INFU's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$108.5M
Liabilities
$55.0M
Debt to equity
1.03
INFU's short-term assets ($32.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INFU's long-term liabilities ($39.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INFU's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INFU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.3M
Investing
-$6.7M
Financing
$3.7M
INFU's operating cash flow ($11.61M)... subscribe to Premium to read more.
Debt Coverage Financials
INFU vs Medical Stocks
Infusystem Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.